- Sarepta Soars as Gene Therapy Stays on Market With Warning Bloomberg
- Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label Sarepta Therapeutics
- Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning Fierce Biotech
- Sarepta Therapeutics Halts ELEVIDYS Shipments for Non-Ambulatory DMD Patients Yahoo Finance
- Sarepta Therapeutics lays off one-third of workforce in drastic cost-cutting The Boston Globe
Source link
